8-Cyclopentyl-1,3-dipropylxanthine (DPCPX, PD-116,948) is a
drug which acts as a
potent and
selectiveantagonist for the
adenosineA1receptor.[1][2] It has high selectivity for A1 over other adenosine receptor subtypes, but as with other
xanthine derivatives DPCPX also acts as a
phosphodiesterase inhibitor, and is almost as potent as
rolipram at inhibiting PDE4.[3] It has been used to study the function of the adenosine A1 receptor in animals,[4][5] which has been found to be involved in several important functions such as regulation of breathing[6] and activity in various regions of the brain,[7][8] and DPCPX has also been shown to produce behavioural effects such as increasing the hallucinogen-appropriate responding produced by the
5-HT2A agonist
DOI,[9] and the dopamine release induced by
MDMA,[10] as well as having interactions with a range of
anticonvulsant drugs.[11][12]
^Vanattou-Saïfoudine N, Gossen A, Harkin A (January 2011). "A role for adenosine A(1) receptor blockade in the ability of caffeine to promote MDMA "Ecstasy"-induced striatal dopamine release". European Journal of Pharmacology. 650 (1): 220–8.
doi:
10.1016/j.ejphar.2010.10.012.
PMID20951694.
^De Sarro G, Donato Di Paola E, Falconi U, Ferreri G, De Sarro A (December 1996). "Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene". European Journal of Pharmacology. 317 (2–3): 239–45.
doi:
10.1016/S0014-2999(96)00746-7.
PMID8997606.
^Chwalczuk K, Rubaj A, Swiader M, Czuczwar SJ (2008). "[Influence of the antagonist of adenosine A1 receptors, 8-cyclopentyl-1 ,3-dipropylxanthine, upon the anticonvulsant activity of antiepileptic drugs in mice]". Przegla̧d Lekarski (in Polish). 65 (11): 759–63.
PMID19205356.